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COST-EFFECTIVENESS OF A EUROPEAN COMMUNITY-BASED 
INTERVENTION: “10,000 STEPS GHENT”
De Smedt D1, De Cocker K1, Cardon G1, De Bourdeaudhuij I1, Annemans L2
1Ghent University, Gent, Belgium; 2Ghent University—Brussels University, Ghent, Belgium
OBJECTIVES: Physical inactivity is linked with inverse health effects and chronic 
disease. The aim of this study was to evaluate the cost-effectiveness of the European 
community-based project “10,000 Steps Ghent.” a published comparative controlled 
trial showed that the intervention resulted in a signiﬁ cant decrease in sedentary time 
and a signiﬁ cant increase in step counts (896 steps/day) and self-reported walking time 
(66 minutes/week). METHODS: A Markov model, with a time horizon of 20 years 
and a cycle length of 1 year was designed in Excel to estimate the development of 
diabetes, cardiovascular events, and colorectal cancer. All individuals start in a health-
state free of events. The model transitions were age dependent and based on epidemio-
logical data. The effect of the intervention was based on published relative risk 
reductions (RRR) related to increased walking time. Costs (from a public payer per-
spective) and utility decrements related to events were obtained from published litera-
ture. To assess the impact of the uncertainty of the parameters on incremental costs 
and QALYs one-way sensitivity analyses and a Monte Carlo analysis were performed. 
RESULTS: Implementing the community-based program increased average QALYs 
with 0.14 to 12.50 QALY and decreased the total costs with approximately c490 to 
c2749. Hence, the intervention program was dominant. One-way sensitivity analyses 
indicated that relative risk reductions had the most pronounced effect on the incre-
mental QALYs and costs, however without changing the conclusion of dominance. 
The results of the Monte Carlo analysis were favorable as well and the intervention, 
based on 5000 simulations, remained dominant. CONCLUSIONS: The community-
based “10,000 Steps Ghent” campaign is a dominant intervention. Sensitivity analyses 
have proved the robustness of the results; hence, implementing this intervention on a 
population-based level could lead to improved health outcomes and reduced costs.
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COST-EFFECTIVENESS OF IMATINIB AS ADJUVANT TREATMENT FOR 
RESECTED GASTROINTESTINAL STROMAL TUMORS (GIST) VERSUS 
BEST SUPPORTIVE CARE: CANADIAN PERSPECTIVE
El Ouagari K1, Pawar V2, Coombs J3, Rubin J2
1Novartis Pharmaceuticals Canada, Dorval, QC, Canada; 2i3 Innovus, Medford, MA, USA; 
3Novartis, Florham Park, NJ, USA
OBJECTIVES: Clinical studies have highlighted the high risk of recurrence following 
complete resection of primary GIST. Published data from the phase III (ACOSOG 
Z9001) trial have demonstrated signiﬁ cant clinical beneﬁ t with adjuvant imatinib 
versus placebo with respect to recurrence-free survival (RFS 98% vs. 83% at 1 year). 
We conducted a health economic evaluation for imatinib as adjuvant therapy for GIST 
that can be used to support this indication. METHODS: A Markov model was used 
to project lifetime outcomes and costs for patients who undergo complete gross resec-
tion of primary GIST. Cost-effectiveness was measured in terms of the incremental 
cost per quality-adjusted life-year (QALY) gained with the addition of imatinib. Prob-
abilities of disease recurrence, resource use, utilities, and costs were derived from 
ACOSOG Z9001 trial and other secondary sources. Results were generated under 
three scenarios regarding the treatment duration with imatinib: 1-year, 3-year, and 
continuous treatment with imatinib. RESULTS: Adding imatinib was projected to 
result in a gain of 0.745, 1.538, and 5.180 QALYs assuming 1-year, 3-year, and 
continuous treatment scenarios, respectively. These clinical beneﬁ ts of imatinib are 
obtained at an additional expected per-patient lifetime cost of $30,042, $81,125, and 
$345,360 assuming 1-year, 3-year, and continuous treatment scenarios, respectively. 
The incremental cost per QALY gained with imatinib was therefore $40,328, $52,760, 
and $66,669 assuming 1-year, 3-year, and continuous treatment scenarios, respec-
tively. Deterministic sensitivity analyses showed the results to be robust with respect 
to variations in assumptions and estimates. The probability that imatinib is cost-
effective given a threshold value of $100,000 per QALY was over 98% in all scenarios. 
CONCLUSIONS: Results of this evaluation suggest that, from a Canadian health-care 
system perspective, imatinib is cost-effective and represents good value for the money 
according to currently accepted standards of cost-effectiveness.
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COST-EFFECTIVENESS OF GEFITINIB VERSUS DOUBLET 
CHEMOTHERAPY IN FIRST-LINE TREATMENT OF NON-SMALL CELL 
LUNG CANCER (NSCLC) IN SWEDEN
Jacob J, Henriksson M, Brattström D
AstraZeneca Nordic MC, Södertälje, Sweden
OBJECTIVES: The IPASS study (NCT00322452) showed that in patients with EGFR 
mutation-positive tumors (EGFRm+), geﬁ tinib signiﬁ cantly increased progression-free 
survival (PFS) compared with doublet chemotherapy, reducing the risk of progression 
by 52% (HR 0.48, 95% CI 0.36 to 0.64, P < 0.001) and increasing median PFS by 
3.2 months (9.5 months vs. 6.3 months) for the ﬁ rst-line treatment of advanced non-
small cell lung cancer (NSCLC). The aim of the study reported here was to evaluate 
the cost-effectiveness of a clinically relevant treatment strategy with geﬁ tinib based on 
data from IPASS. The strategy with geﬁ tinib involves EGFR mutation testing prior to 
treatment, followed by selective geﬁ tinib treatment of EGFRm+ patients and doublet 
chemotherapy for EGFRm- patients and patients with unknown mutation status, and 
is compared to treating all patients with doublet chemotherapy without mutation 
testing. METHODS: A Markov model was developed to integrate IPASS study data 
with external data on costs and quality of life. The model estimated costs and QALYs 
from a lifetime horizon for each treatment strategy. The key clinical data inputs were 
event rates of PFS and overall survival data. Other important parameters, e.g., preva-
lence of EGFRm+, cost of EGFR-diagnostics, resource utilization, and utility estimates 
were retrieved from the literature. RESULTS: The test and treat strategy, including 
geﬁ tinib, was associated with a QALY gain of 0.0116 at an incremental cost of c300 
yielding a cost per QALY gained of c25,900. CONCLUSIONS: This cost-effectiveness 
analysis of the IPASS study demonstrates that testing patients for EGFR status, fol-
lowed by geﬁ tinib treatment for EGFR m+ patients is a cost-effective option compared 
to treating all patients with doublet chemotherapy in a Swedish setting.
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COST-UTILITY ANALYSIS OF DASATINIB AS A SECOND-LINE 
TREATMENT IN THE CHRONIC PHASE OF CHRONIC MYELOID 
LEUKAEMIA IN RUSSIA
Kuznetzov S1, Mungapen LJ2, Samyshkin Y2, Jakouloff DE3, Sbarigia U4, van Baardewijk M4
1Haematology Research Centre, Moscow, Russia; 2IMS Health, London, UK; 3BMS, Moscow, 
Russia; 4BMS, Braine l’Alleud, Belgium
OBJECTIVES: To evaluate the cost-effectiveness of dasatinib 100 mg once daily in 
second-line therapy for chronic myeloid leukemia (CML) patients in the chronic phase 
(CP) resistant to imatinib 400 mg compared with imatinib 800 mg and nilotinib 
800 mg in Russia. METHODS: A Markov cost-utility model was developed to esti-
mate lifetime outcomes and resource use reﬂ ecting treatment practice for CML patients 
in Russia. Treatment efﬁ cacy, disease progression, and rates of adverse events in the 
model were based on published multicenter randomized controlled trials. RESULTS: 
Dasatinib appeared to be dominant over imatinib and nilotinib in CP-CML in the 
Russian setting. Incremental life expectancies were 0.17 years and 0.26 years when 
comparing dasatinib with imatinib and nilotinib, respectively; quality-adjusted life-
years (QALYs) gains were of 0.18 and 0.22 QALY versus imatinib and nilotinib, 
respectively. The life-years and QALY gains on dasatinib treatment were due to a 
larger proportion of patients who achieved complete cytogenic response (CCyR). 
Mean cost saving per patient over a lifetime horizon with dasatinib were Rubles (RUB) 
1,364,220 versus imatinib and RUB 778,621 versus nilotinib. Limitations of the model 
include a lack of direct comparative efﬁ cacy data at licensed doses, which precluded 
formal indirect comparison. CONCLUSIONS: Dasatinib was a dominating strategy, 
resulting in outcome gains (greater life expectancy and greater quality-adjusted life 
expectancy) and cost saving compared both to nilotinib and high-dose imatinib in 
CP-CML patients. Expanding access to new tyrosine kinase inhibitors for the treat-
ment of CP-CML in Russia would ensure a greater choice of modern and effective 
therapies.
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COST-EFFECTIVENESS OF DIGITAL MAMMOGRAPHY IN A BREAST 
CANCER POPULATION-BASED SCREENING PROGRAM
Comas M1, Arrospide A2, Mar J2, Roman R1, Sala M1, Hernandez C1, Castells X
1Hospital del Mar-IMIM, CIBER de Epidemiología y Salud Pública (CIBERESP), Barcelona, 
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OBJECTIVES: The introduction of digital mammography presents beneﬁ ts at the 
technological. However, there are doubts about its impact on the effectiveness of 
breast cancer screening. The aim of this study was to analyze the cost-effectiveness of 
the introduction of digital mammography in a population-based breast cancer screen-
ing program. METHODS: A discrete-event simulation model was implemented includ-
ing the processes under a breast cancer screening program and the natural history of 
breast cancer. The screening events included: invitation (biennial) of the target popula-
tion (women aged 50–69 years), participation, screening test, conﬁ rmatory tests after 
a positive mammography result, cancer diagnosis, and treatment. Natural history of 
breast cancer included the following health states: no cancer, preclinical (nonsymp-
tomatic) cancer, clinical (or symptomatic) cancer, and death. Natural history was 
modeled as time until a change of health state, and health states were managed using 
attributes in order to condition the sensitivities and speciﬁ cities of the tests to the 
current health state of the woman. Interval cancers were also detected according to 
the health state. Digital and analogical mammography had the same sensitivity, but 
different speciﬁ cities were applied according to type of mammography and also initial 
or successive screening. Cost-effectiveness was calculated under a 20-year screening 
scenario and ﬁ ve simulations. RESULTS: Simulation started with a target population 
of 28,020 women. Other 29,552 women were enrolled in the target population during 
the simulated 20 years. This population resulted in 56,136 screening mammograms. 
The number conﬁ rmatory tests needed was 1864 under analogical mammography and 
1724 under digital screening. Screen-detected cancers were 344 with analogical screen-
ing and 312 with digital screening. The overall ICER was c349.14. CONCLUSIONS: 
Results suggest that population-based breast cancer screening with digital mammog-
raphy is cost-effective. It does not improve the results of conventional analogical 
mammography, but it reduces the cost in conﬁ rmatory tests.
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COST-EFFECTIVENESS ANALYSIS OF ADDING HPV VACCINATION TO 
CERVICAL CANCER SCREENING PROGRAM IN HUNGARY
Vokó Z1, Nagyjanosi L2, Kalo Z1
1Eötvös Loránd University, Budapest, Hungary; 2Syreon Research Institute, Budapest, Hungary
OBJECTIVES: Despite opportunistic and organized screening, mortality of cervical 
cancer is still high in Hungary in international comparison. The study aimed to 
